Complement C5 inhibitor eculizumab has a great impact on the treatment of patients with
paroxysmal nocturnal hemoglobinuria (PNH). However, this treatment success has a major …

Eculizumab is indicated for the therapy of patients with symptomatic paroxysmal nocturnal
hemoglobinuria (PNH). Due to inhibition of terminal complement cascade, patients on …

Paroxysmal nocturnal haemoglobinuria (PNH) is a rare acquired haematopoietic stem cell
disease which causes defects in complement inhibiting proteins. The disease presents …

Eculizumab is a novel monoclonal antibody that inhibits complement‐mediated hemolysis in
patients with paroxysmal nocturnal hemoglobinuria (PNH). Complement deficiency is a well …

Eculizumab is a monoclonal antibody that binds with high affinity to the complement protein
C5, preventing terminal complement-mediated intravascular haemolysis in patients with …

Paroxysmal nocturnal haemoglobinuria (PNH) is a rare acquired haematopoietic stem cell
disease characterized by complement-mediated intravascular hemolysis, thrombosis, and …

Eculizumab, a humanized anti–complement C5 monoclonal antibody (mAb) for treatment of
paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome …

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease caused by a somatic
mutation of the PIGA gene, which results in the absence of the glycosylphosphatidylinositol …

A 25-year-old male was admitted for evaluation of fatigue, and was found to have severe
anaemia with a haemoglobin level of 6.4 gr%, MCV 118 fL, 116 000 reticulocytes/μL (7%) …

Abstract Learning Objectives After completing this course, the reader will be able to:
Describe the mechanism of action of eculizumab in PNH. Discuss the efficacy findings upon …